利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.011 秒)

    IN VIVO METHOD FOR THE EVALUATION OF A COMPOUND-TARGET INTERACTION
    1.
    发明公开
    IN VIVO METHOD FOR THE EVALUATION OF A COMPOUND-TARGET INTERACTION 审中-公开
    体内方法用于评估复合靶相互作用

    公开(公告)号：EP2596125A1

    公开(公告)日：2013-05-29

    申请号：EP11730204.2

    申请日：2011-06-20

    申请人： CELLZOME AG

    发明人： DREWES, Gerard ,  HOPF, Carsten ,  KRUSE, Ulrich ,  NEUBAUER, Gitte

    IPC分类号： C12Q1/48 ,  G01N33/50

    CPC分类号： G01N33/573 ,  G01N33/5088 ,  G01N2333/91215 ,  G01N2500/00

    摘要： The invention relates to a method for evaluation of a compound-target interaction in vivo, comprising the steps of administering the compound to an animal, taking a body fluid sample of the animal, determining the concentration of the compound in the body fluid sample, taking a cellular sample of the animal containing the target, preparing a protein preparation of said cellular sample, providing an immobilised ligand capable of binding to the target, contacting the protein preparation with the immobilised ligand under conditions allowing the formation of a complex between the immobilised ligand and the target, determining the amount of complexes formed in step, and correlating the amount of complexes with the concentration of the compound in the body fluid sample.

    PROCESSES FOR THE IDENTIFICATION OF MEDICAL TARGETS BY SCREENING AN ACTIVE AGENT FOR BINDING INTERACTIONS
    3.
    发明公开
    PROCESSES FOR THE IDENTIFICATION OF MEDICAL TARGETS BY SCREENING AN ACTIVE AGENT FOR BINDING INTERACTIONS 审中-公开
    一种用于识别靶向药物BY结合相互作用进行的审评的药物

    公开(公告)号：EP1634073A2

    公开(公告)日：2006-03-15

    申请号：EP04731591.6

    申请日：2004-05-07

    申请人： CELLZOME AG

    发明人： SUPERTI-FUGA, Giulio ,  KRUSE, Ulrich ,  RYBIN, Vladimir ,  NEUBAUER, Gitte

    IPC分类号： G01N33/53

    CPC分类号： G01N33/543 ,  G01N33/6803 ,  G01N33/94 ,  G01N2333/525 ,  G01N2500/04

    摘要： The present invention relates to a process for the isolation and identification of pharmaceutically relevant target compounds (TC) from a sample, said sample being derived from a living organism, wherein said target compound(s) bind(s) to a compound of interest (COI) under physiological conditions, said compound of interest (COI) being associated with a given impaired condition or disease. This process involves the isolation and the purification of the complex(es) formed by the compound. The present invention also relates to a process for the identification of a pharmaceutically effective compound useful for preventing and/or treating a given impaired condition or disease, wherein said compound is identified by its binding to a relevant target compound (TC) that has been identified and isolated according to the above mentioned process. Furthermore, the present application concerns a process for the identification of new uses (i.e. medical indications) of an active agent involving identifying diseases associated with the binding partner(s) of the active agent.